LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-08-15
Case ID: NM_000435.2_c.3278G_T_20260815_232555
Framework: ACMG/AMP 2015
Variant classification summary

NM_000435.2:c.3278G>T

NOTCH3  · NP_000426.2:p.(Cys1093Phe)  · NM_000435.2
GRCh37: chr19:15290932 C>A  ·  GRCh38: chr19:15180121 C>A
Gene: NOTCH3 Transcript: NM_000435.2
Final call
Likely Pathogenic
PM1 moderate PM2 supporting PP2 supporting PP3 strong
All criteria require review: For research and educational purposes only.
Gene
NOTCH3
Transcript
NM_000435.2
Protein
NP_000426.2:p.(Cys1093Phe)
gnomAD AF
ClinVar
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
PM1 (Moderate): p.(Cys1093Phe) alters a cysteine in the NOTCH3 EGF-like repeat hotspot where CADASIL-causing variants cluster.
2
PM2 (Supporting): the variant is absent from gnomAD v2.1, v4.1, and gnomAD-Canada v1.0.
3
PP2 (Supporting): missense, especially cysteine-altering, variants are the established NOTCH3/CADASIL disease mechanism.
4
PP3 (Strong): REVEL 0.962 exceeds the >=0.932 ClinGen SVI PP3_Strong threshold.
5
Overall: Likely Pathogenic - one Strong + one Moderate + two Supporting meet the generic ACMG/AMP 2015 Likely Pathogenic combination.
Final determination: Generic ACMG/AMP 2015 fallback: PP3(strong) + PM1(moderate) + PM2(supporting) + PP2(supporting) satisfies the Likely Pathogenic combination (1 PS-level + 1 PM + 2 PP) and falls short of Pathogenic thresholds.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: p.(Cys1093Phe) is a missense change, so no null-variant mechanism (nonsense-mediated decay, truncation, or splice disruption) applies.
pvs1_generic_framework generic_acmg_combination_rules
PS1 Not assessed Not assessed: ClinVar returned no prior pathogenic classification for any other nucleotide change producing the identical amino acid change, so no comparator exists.
clinvar
PS2 Not assessed Not assessed: no parental testing, maternity/paternity confirmation, or de novo observation was available for this variant.
PS3 Not assessed Not assessed: no functional assay data on this variant was available, and the literature search returned zero relevant studies.
PS4 Not assessed Not assessed: no affected-case counts, case-control enrichment, or clinical cohort evidence was available for this variant.
PM1 Met Met (Moderate): p.(Cys1093Phe) alters a cysteine within the NOTCH3 EGF-like repeat domain, a mutation-dense hotspot where CADASIL-causing cysteine variants cluster.
pvs1_gene_context
PM2 Met Met (Supporting): the variant is absent from gnomAD v2.1, v4.1, and gnomAD-Canada v1.0, with no observed allele count or frequency.
gnomad_v2 gnomad_v4 gnomad_canada
PM3 Not assessed Not assessed: no second pathogenic allele, phase result, or recessive-disease context was established for this variant.
PM4 N/A Not applicable: this missense change does not alter protein length, so the in-frame insertion/deletion and stop-loss criterion does not apply.
pvs1_generic_framework generic_acmg_combination_rules
PM5 Not assessed Not assessed: no prior pathogenic missense change at codon 1093 was available as a comparator.
pm5_candidates clinvar
PM6 Not assessed Not assessed: no unconfirmed de novo observation or parental testing was provided.
PP1 Not assessed Not assessed: no affected relatives, informative meioses, or segregation results were provided.
PP2 Met Met (Supporting): missense variants - especially cysteine-altering changes in the EGF-like repeats - are the established NOTCH3/CADASIL disease mechanism.
pvs1_gene_context
PP3 Met Met (Strong): REVEL score 0.962 exceeds the >=0.932 ClinGen SVI PP3_Strong calibration threshold.
revel
PP4 Not assessed Not assessed: no patient phenotype or diagnostic features were provided to establish a highly specific presentation.
PP5 Not met Not met: the exact variant is absent from ClinVar, with no expert-panel Pathogenic or Likely Pathogenic assertion.
clinvar
BA1 Not met Not met: the variant is absent from gnomAD v2.1, v4.1, and gnomAD-Canada v1.0, so no allele frequency reaches the stand-alone benign threshold.
gnomad_v2 gnomad_v4 gnomad_canada
BS1 Not met Not met: no population allele frequency was observed in gnomAD, so the frequency is not higher than expected for the disease.
gnomad_v2 gnomad_v4 gnomad_canada
BS2 Not assessed Not assessed: no unaffected adult homozygotes or hemizygotes carrying the variant were reported.
BS3 Not assessed Not assessed: no functional assay evidence of normal (wild-type-like) protein function was available for this variant.
BS4 Not assessed Not assessed: no unaffected relatives tested or informative non-segregation data were provided.
BP1 Not met Not met: missense variation is the established NOTCH3 disease mechanism, so the truncation-predominant premise of BP1 does not apply.
pvs1_gene_context
BP2 Not assessed Not assessed: no phase, co-occurring pathogenic variant, or segregation data was available to evaluate the criterion.
BP3 N/A Not applicable: this missense change does not alter protein length within a repetitive region.
pvs1_generic_framework generic_acmg_combination_rules
BP4 Not met Not met: REVEL 0.962 strongly supports pathogenicity and no splice disruption is predicted, so no benign-leaning computational signal exists.
revel spliceai
BP5 Not assessed Not assessed: no alternative molecular explanation for the phenotype was identified.
BP6 Not met Not met: the exact variant is absent from ClinVar, with no expert-panel Benign or Likely Benign assertion.
clinvar
BP7 N/A Not applicable: this missense change alters the encoded protein sequence, so the silent-variant premise of BP7 does not hold.
generic_acmg_combination_rules
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.